MACROGENICS INC. - COMMON STOCK

MacroGenics to Participate in Upcoming Investor Conference

08 Jun 2022 15:01:00 By Nasdaq GlobeNewswire

MacroGenics Announces Appointment of William Heiden to Board of Directors

23 May 2022 15:01:00 By Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conference

17 May 2022 15:01:00 By Nasdaq GlobeNewswire

MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results

03 May 2022 15:01:00 By Nasdaq GlobeNewswire

MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call

25 Apr 2022 15:11:56 By Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conferences

03 Mar 2022 15:01:00 By Nasdaq GlobeNewswire

MacroGenics Provides Update on Corporate Progress and 2021 Financial Results

24 Feb 2022 15:01:01 By Nasdaq GlobeNewswire

MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call

14 Feb 2022 15:01:00 By Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conferences

03 Feb 2022 15:01:00 By Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conferences

03 Nov 2021 15:01:00 By Nasdaq GlobeNewswire

MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results

02 Nov 2021 15:01:00 By Nasdaq GlobeNewswire

MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call

26 Oct 2021 15:30:00 By Nasdaq GlobeNewswire

MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress

16 Sep 2021 01:45:00 By Nasdaq GlobeNewswire

MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021

16 Sep 2021 01:45:00 By Nasdaq GlobeNewswire

MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress

12 Sep 2021 18:00:00 By Nasdaq GlobeNewswire

MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer

07 Sep 2021 15:30:00 By Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conferences

02 Sep 2021 15:30:00 By Nasdaq GlobeNewswire

MacroGenics to Participate in Upcoming Investor Conferences

05 Aug 2021 15:30:00 By Nasdaq GlobeNewswire

MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results

29 Jul 2021 15:01:00 By Nasdaq GlobeNewswire

MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call

22 Jul 2021 15:05:01 By Nasdaq GlobeNewswire